Inhibition of p38 MAPK α/β reduces ischemic injury and does not block protective effects of preconditioning

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 280, Issue 2 49-2, 2001, Pages

  Schneider, Sharron ^a,b   Chen, Weina ^c   Hou, Janet ^a   Steenbergen, Charles ^c   Murphy, Elizabeth ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

31P nuclear magnetic resonance; Intracellular pH; Left ventricular developed pressure; Necrosis; SB 202190

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; MITOGEN ACTIVATED PROTEIN KINASE; TRIPHENYLTETRAZOLIUM;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG SCREENING; ENZYME INHIBITION; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HEART PROTECTION; ISOLATED HEART; MALE; NONHUMAN; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; RAT;

EID: 0035008371     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.2001.280.2.h499     Document Type: Article

References (39)

1. Armstrong SC, Delacey M, and Ganote CE. Phosphorylation state of hsp27 and p38 MAPK during preconditioning and protein phosphatase inhibitor protection of rabbit cardiomyocytes. J Mol Cell Cardiol 31: 555-567, 1999.
2. Bergmeyer, EH. Methods of Enzymatic Analysis (2nd ed.). New York: Academic, 1974.
3. Bogoyevitch MA, Gillespie-Brown J, Ketterman AJ, Fuller SJ, Ben-Levy R, Ashworth A, Marshall CJ, and Sugden PH. Stimulation of the stress-activated mitogen-activated protein kinase subfamilies in perfused heart. p38/RK mitogen-activated protein kmases and c-Jun N-terminal kinases are activated by ischemia/reperfusion. Circ Res 79: 162-73, 1996.
4. Cohen P. The search for physiological substrates of MAP and SAP kinases in mammalian cells. Trends Cell Biol 7: 353-361, 1997.
5. Cuenda A, Rouse J, Doza YN, Meier R, Cohen P, Gallagher TF, Young PR, and Lee JC. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett 364: 229-233, 1995.
6. Deak M, Clifton AD, Lucocq LM, and Alessi DR. Mitogen-and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may mediate activation of CREB. EMBO J 17: 4426-4441, 1998.
7. Force T, Pombo CM, Avruch JA, Bonventre JV, and Kyriakis JM. Stress-activated protein kinases in cardiovascular disease. Circ Res 78: 947-953, 1996.
8. Franke TF, Kaplan DR, and Cantley LC. PI3K: downstream AKTion blocks apoptosis. Cell 88: 435-437, 1997.
9. Ganote CE and Humphrey SM. Effects of anoxic or oxygenated reperfusion in globally ischemic, isovolumic, perfused rat hearts. Am J Pathol 120: 129-145, 1985.
10. Ganote CE, Seabra-Gomes R, Nayler WG, and Jennings RB. Irreversible myocardial injury in anoxic perfused rat hearts. Am J Pathol 80: 419-450, 1975.
11. Garlick PB, Radda GK, and Seeley PJ. Studies of acidosis in the ischaemic heart by phosphorus nuclear magnetic resonance. Biochem J 184: 547-554, 1979.
12. Gould GW, Cuenda A, Thomson FJ, and Cohen P. The activation of distinct mitogen-activated protein kinase cascades is required for the stimulation of 2-deoxyglucose uptake by interleukin-1 and insulin-like growth factor-1 in KB cells. Biochem J 311: 735-738, 1995.
13. Guay J, Lambert H, Gingras-Breton G, Lavoie JN, Huot J, and Landry J. Regulation of actin filament dynamics by p38 MAP kinase-mediated phosphorylation of heat shock protein 27. J Cell Sci 110: 357-368, 1997.
14. Jennings RB, Murry CE, Steenbergen C Jr, and Reimer KA. Development of cell injury in sustained acute ischemia. Circulation 82: II2-II12, 1990.
15. Kyriakis JM and Avruch J. Protein kinase cascades activated by stress and inflammatory cytokines. Bioessays 18: 567-577, 1996.
16. Lali FV, Hunt AE, Turner SJ, and Foxwell BM. The pyridinyl imidazole inhibitor SB203580 blocks phosphoinositide-dependent protein kinase activity, protein kinase B phosphorylation, and retinoblastoma hyperphosphorylation in interleukin-2stimulated T cells independently of p38 mitogen-activated protein kinase. J Biol Chem 275: 7395-7402, 2000.
17. Lasley RD, Anderson GM, and Mentzer RM. Ischemic and hypoxic preconditioning enhances post ischemic recovery of function in rat heart. Cardiovasc Res 27: 565-570, 1993.
18. Lee JC, Laydon JT, MPC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Heys JR, Landvatter SW, Strickler JE, McLaughlin MM, Siemens IR, Fisher SM, Livi GP, White JR, Adams JL, and Young PR. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372: 739-746, 1994.
19. Liu Y and Downey JM. Ischemic preconditioning protects against infarction in rat heart. Am J Physiol Heart Circ Physiol 263: H1107-H1112, 1992.
20. Ma XL, Kumar S, Feng G, Lounden CS, Lopez BL, Christopher TA, Wang C, Lee JC, Feuerstein GZ, and Yue T. Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. Circulation 99: 1685-1691, 1999.
21. Mackay K and Mochly-Rosen D. An inhibitor of p38 mitogen-activated protein kinase protects neonatal cardiac myocytes from ischemia. J Biol Chem 274: 6272-6279, 1999.
22. Maulik N, Watanabe M, Zu YL, Huang CK, Cordis GA, Schley JA, and Das DK. Ischemic preconditioning triggers the activation of MAP kinases and MAPKAP kinase 2 in rat hearts. FEBS Lett 396: 233-237, 1996.
23. Murry CE, Jennings RB, and Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74: 1124-1136, 1986.
24. Murry CE, Richard VJ, Reimer KA, and Jennings RB. Ischemic preconditioning slows energy metabolism and delays ultrastructural damage during a sustained ischemic episode. Circ Res 66: 913-931, 1990.
25. Nakano A, Baines CP, Kim SO, Pelech SL, Downey JM, Cohen MV, and Critz SD. Ischemic preconditioning activates MAPKAPK2 in the isolated rabbit heart: evidence for involvement of p38 MAPK. Circ Res 86: 144-151, 2000.
26. Ping P and Murphy E. Role of p38 mitogen-activated protein kinases in preconditioning: a detrimental factor or a protective kinase? Circ Res 86: 921-922, 2000.
27. Ping P, Zhang J, Huang S, Cao X, Tang XL, Li RC, Zheng YT, Qiu Y, Clerk A, Sugden P, Han J, and Bolli R. PKC-dependent activation of p46/p54 JNKs during ischemic preconditioning in conscious rabbits. Am J Physiol Heart Circ Physiol 277: H1771-H1785, 1999.
28. Richard VJ, Brooks SE, Jennings RB, and Reimer KA. Effect of a critical coronary stenosis on myocardial neutrophil accumulation during ischemia and early reperfusion in dogs. Circulation 80: 1805-1815, 1989.
29. Saurin AT, Heads RJ, Foley C, Wang Y, and Marber MS. Inhibition of P38 alpha activation may underlay protection in surrogate model of ischemic preconditioning. Circulation 100: 1-492, 1999.
30. Steenbergen C, Perlman ME, London RE, and Murphy E. Mechanism of preconditioning. Ionic alterations. Circ Res 72: 112-125, 1993.
31. Sugden PH and Clerk A. "Stress-responsive" mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium. Circ Res 83: 345-352, 1998.
32. Sweeney G, Somwar R, Ramlal T, Volchuk A, Ueyama A, and Klip A. An inhibitor of p38 mitogen-activated protein kinase prevents insulin-stimulated glucose transport but not glucose transporter translocation in 3T3-L1 adipocytes and L6 myotubes. J Biol Chem 274: 10071-10078, 1999.
33. Tong H, Chen W, London RE, Murphy E, and Steenbergen C. Preconditioning enhanced glucose uptake is mediated by p38 MAP kinase not by phosphatidylinositol 3-kinase. J Biol Chem 275: 11981-11986, 2000.
34. Vivaldi MT, Kloner RA, and Schoen FJ. Triphenyltetrazolium staining of irreversible ischemic injury following coronary artery occlusion in rats. Am J Pathol 121: 522-530, 1985.
35. 2 are abrogated by an inhibitor of the p38 mitogen-activated protein kinase cascade in human neutrophils. Biochem J 319: 17-20, 1996.
36. Weinbrenner C, Liu GS, Cohen MV, and Downey JM. Phoshorylation of tyrosine 182 of p38 mitogen-activated protein kinase correlates with the protection of preconditioning in the rabbit heart. J Cell Molec Cardiol 29: 2383-2391, 1997.
37. Weiss RG, de Albuquerque CP, Vandegaer K, Chacko VP, and Gerstenblith G. Attenuated glycogenolysis reduces glycolytic catabolite accumulation during ischemia in preconditioned rat hearts. Circ Res 79: 435-446, 1996.
38. Yellon DM, Alkhulaifi AM, and Pugsley WB. Preconditioning the human myocardium. Lancet 342: 276-277, 1993.
39. Young PR, McLaughlin MM, Kumar S, Kassis S, Doyle ML, McNulty D, Gallagher TF, Fisher S, McDonnell PC, Carr SA, Huddleston MJ, Seibel G, Porter TG, Livi GP, Adams JL, and Lee JC. Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site. J Biol Chem 272: 12116-12121, 1997.